Stockreport

Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term [Yahoo! Finance]

ARS Pharmaceuticals, Inc.  (SPRY) 
PDF ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. With the latest financial year loss of US$54m and a trailing-t [Read more]